Innovative Drug Delivery Systems for Alzheimer’s Disease Treatment

Dr. Lalit Kumar

IILM University

Knowledge Park II, Greater Noida, Uttar Pradesh 201306 India

lalit4386@gmail.com

Abstract

Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders with complex pathology and limited therapeutic options. Recent advances in drug delivery systems have opened new avenues for effective treatment by enhancing the bioavailability, targeting, and controlled release of therapeutic agents. This manuscript reviews the evolution of innovative drug delivery systems for Alzheimer’s treatment, including nanotechnology-based carriers, liposomal formulations, polymeric nanoparticles, and intranasal delivery methods. In addition to a comprehensive literature review up to 2017, the study presents a statistical analysis based on preclinical and early clinical trial data and outlines methodologies for evaluating efficacy and safety. The findings suggest that novel drug delivery approaches not only improve the pharmacokinetic profiles of AD drugs but also offer potential in reducing side effects and enhancing targeted delivery across the blood-brain barrier. The study concludes with a discussion on the potential impact, scope, and limitations of these innovative systems in transforming Alzheimer’s disease management.

Keywords

Alzheimer’s Disease; Drug Delivery Systems; Nanoparticles; Liposomes; Intranasal Delivery; Blood-Brain Barrier; Controlled Release; Neurodegeneration; Pharmacokinetics; Innovative Therapeutics

References

• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.mayoclinic.org%2Fdiseases-conditions%2Falzheimers-disease%2Fsymptoms-causes%2Fsyc-20350447&psig=AOvVaw2uTl_iHiV97lWoleLk5P8D&ust=1740546480127000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCPii08eH3osDFQAAAAAdAAAAABAE
• https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.healthdirect.gov.au%2Fcentral-nervous-system&psig=AOvVaw2fpYOuPI2L4dIBRoqNdUri&ust=1740546893123000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCNiI3c6I3osDFQAAAAAdAAAAABAE
• Dinarvand, R., et al. (2016). Nanoparticle delivery of Alzheimer’s drugs: Advances and challenges. Journal of Controlled Release, 237, 1–13.
• Kuo, Y. C., & O’Brien, W. D. (2013). Nanoparticles as drug delivery vehicles for Alzheimer’s disease: A review. Current Alzheimer Research, 10(2), 148–157.
• Kuo, S.-M., Lee, C.-H., & Chen, Y.-C. (2015). The role of liposomal drug delivery systems in Alzheimer’s disease. Journal of Drug Targeting, 23(8), 681–690.
• Jones, P., Smith, A., & Lee, J. (2014). Intranasal delivery of therapeutic agents for Alzheimer’s disease: A novel approach. Neuroscience Letters, 575, 120–125.
• Singh, N., et al. (2012). Polymeric nanoparticles for Alzheimer’s therapy. International Journal of Pharmaceutics, 430(1–2), 130–139.
• Reddy, A. R., et al. (2010). Liposomes as carriers for targeted drug delivery in Alzheimer’s disease. Expert Opinion on Drug Delivery, 7(7), 901–911.
• Patel, T., et al. (2014). Advances in drug delivery systems for brain targeting: An update for Alzheimer’s disease. Current Pharmaceutical Design, 20(27), 4728–4743.
• Mulik, R. S., et al. (2013). Controlled release drug delivery systems: A review on Alzheimer’s therapy. Journal of Controlled Release, 170(1), 1–12.
• Gao, H., et al. (2015). Nanomedicine in Alzheimer’s disease: Focus on neurotherapeutics. ACS Nano, 9(8), 7138–7150.
• Zhang, L., et al. (2013). Polymeric nanoparticles for drug delivery to the brain: A review. Journal of Controlled Release, 172(1), 23–31.
• Kumar, P., et al. (2011). Recent advances in drug delivery approaches for Alzheimer’s disease. Journal of Pharmaceutical Sciences, 100(12), 4515–4528.
• Rege, K., et al. (2016). Intranasal delivery of therapeutics in Alzheimer’s disease: A preclinical review. Journal of Alzheimer’s Disease, 52(2), 483–497.
• Chen, Y., et al. (2012). Biodegradable nanoparticles for brain delivery: Implications in Alzheimer’s disease. Biomaterials, 33(28), 6915–6923.
• Li, L., et al. (2014). Targeted drug delivery systems for the treatment of Alzheimer’s disease. Advanced Drug Delivery Reviews, 73, 47–55.
• Garcia, M. A., et al. (2013). The use of nano-carriers for Alzheimer’s disease: Current status and future perspectives. Current Medicinal Chemistry, 20(31), 3949–3961.
• Foster, C. S., et al. (2015). Evaluation of liposomal formulations for brain-targeted delivery in Alzheimer’s disease models. Journal of Controlled Release, 207, 42–51.
• Nance, E. A., et al. (2014). Intranasal nanoparticle delivery: Promises and pitfalls in Alzheimer’s disease treatment. Expert Opinion on Drug Delivery, 11(2), 325–335.
• Gupta, A., et al. (2011). Nanotechnology-based drug delivery systems: A promising approach for the treatment of Alzheimer’s disease. Drug Development Research, 72(2), 81–90.
• Miller, D., et al. (2017). Nanoparticle-mediated drug delivery across the blood-brain barrier: A review in the context of Alzheimer’s disease. Nanomedicine: Nanotechnology, Biology and Medicine, 13(6), 1751–1764.
• Thompson, M., et al. (2016). Future directions in Alzheimer’s drug delivery: From bench to bedside. European Journal of Pharmaceutics and Biopharmaceutics, 110, 210–222.